Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission

Ann Neurol. 1992 Apr;31(4):366-73. doi: 10.1002/ana.410310404.

Abstract

We studied the in vitro electrical activity of rat neostriatal neurons following chronic neuroleptic treatment. In haloperidol-treated rats, unlike naive animals, activation of neostriatal D2 dopamine receptors induced a potent presynaptic inhibition of glutamate-mediated excitatory synaptic potentials. Haloperidol treatment did not affect the intrinsic membrane properties of the neostriatal neurons. Pre- and postsynaptic physiological responses to direct and indirect gamma-aminobutyric acid (GABA)-ergic and cholinergic agonists were not affected by chronic haloperidol treatment. These findings suggest that movement disorders induced by chronic neuroleptic treatment may result, at least in part, from a hypersensitivity of presynaptic D2 dopamine receptors regulating the release of glutamate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism
  • Animals
  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / therapeutic use
  • Corpus Striatum / metabolism*
  • Ergolines / pharmacology
  • Glutamine / physiology*
  • Haloperidol / pharmacology*
  • Parasympathomimetics / pharmacology
  • Quinpirole
  • Rats
  • Rats, Inbred Strains
  • Receptors, Dopamine / drug effects*
  • Receptors, Dopamine D2
  • Receptors, GABA-A / physiology
  • Receptors, Muscarinic / physiology
  • Synaptic Transmission / drug effects*
  • Synaptic Transmission / physiology
  • Time Factors

Substances

  • Antipsychotic Agents
  • Ergolines
  • Parasympathomimetics
  • Receptors, Dopamine
  • Receptors, Dopamine D2
  • Receptors, GABA-A
  • Receptors, Muscarinic
  • Glutamine
  • Quinpirole
  • Haloperidol